Jasper Therapeutics (NASDAQ:JSPR) Earns “Market Outperform” Rating from JMP Securities

Jasper Therapeutics (NASDAQ:JSPR)‘s stock had its “market outperform” rating reaffirmed by analysts at JMP Securities in a research report issued on Friday, Benzinga reports. They presently have a $70.00 price objective on the stock. JMP Securities’ price objective would indicate a potential upside of 280.02% from the stock’s previous close.

A number of other equities analysts have also commented on JSPR. Stifel Nicolaus initiated coverage on Jasper Therapeutics in a research note on Thursday, June 27th. They issued a “buy” rating and a $86.00 price objective on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $65.00 price objective on shares of Jasper Therapeutics in a research note on Tuesday, August 13th. Evercore ISI restated an “outperform” rating and issued a $65.00 target price on shares of Jasper Therapeutics in a report on Monday, August 26th. Royal Bank of Canada decreased their price target on Jasper Therapeutics from $70.00 to $68.00 and set an “outperform” rating for the company in a report on Wednesday, August 14th. Finally, BTIG Research initiated coverage on Jasper Therapeutics in a research note on Monday, July 8th. They issued a “buy” rating and a $90.00 price objective on the stock. Ten equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $73.00.

Jasper Therapeutics Stock Performance

Shares of NASDAQ:JSPR traded down $0.42 during midday trading on Friday, hitting $18.42. 20,638 shares of the stock were exchanged, compared to its average volume of 146,811. The business’s 50-day moving average price is $19.68 and its 200 day moving average price is $22.56. Jasper Therapeutics has a 12 month low of $4.00 and a 12 month high of $31.01. The stock has a market capitalization of $277.48 million, a price-to-earnings ratio of -3.27 and a beta of 2.22.

Jasper Therapeutics (NASDAQ:JSPR) last announced its quarterly earnings results on Tuesday, August 13th. The company reported ($0.97) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.09) by $0.12. As a group, sell-side analysts expect that Jasper Therapeutics will post -4.16 EPS for the current year.

Institutional Investors Weigh In On Jasper Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the company. American Century Companies Inc. lifted its holdings in shares of Jasper Therapeutics by 27.1% in the 2nd quarter. American Century Companies Inc. now owns 14,204 shares of the company’s stock worth $322,000 after purchasing an additional 3,032 shares in the last quarter. Virtu Financial LLC acquired a new position in shares of Jasper Therapeutics during the first quarter valued at about $306,000. Rhumbline Advisers bought a new stake in shares of Jasper Therapeutics during the second quarter worth about $300,000. Concurrent Investment Advisors LLC acquired a new stake in shares of Jasper Therapeutics in the 1st quarter worth about $599,000. Finally, Bank of New York Mellon Corp acquired a new stake in shares of Jasper Therapeutics in the 2nd quarter worth about $740,000. Institutional investors and hedge funds own 79.85% of the company’s stock.

About Jasper Therapeutics

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.